Delivery Order SPE2DB24D1205-SPE2DB25FCXTR
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $38,125.72 to AmerisourceBergen Drug Corp for the supply of Tolvaptan 30 mg tablets in unit dose packaging of 10 tablets per package. This is a firm fixed price, non-set-aside contract with a completion date of May 28, 2025. The award was issued on May 27, 2025, with performance to be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Tolvaptan is a vasopressin receptor antagonist used primarily...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Tolvaptan 30 mg tablets in unit-dose packaging of 10 units, with a ceiling value of $18,283.30. The award, issued on October 24, 2025, utilizes firm fixed-price pricing with an ultimate completion date of October 27, 2025. This is a non-set-aside competitive award with performance at AmerisourceBergen's Conshohocken, Pennsylvania location, and the delivery order is structured as a child contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 14, 2025, for the supply of Tolvaptan 15 mg tablets in unit-dose packaging of 10 units. This competitive award, valued at $44,199.07 on a firm fixed-price basis, is scheduled for completion by November 17, 2025, with performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $22,092.55 to AmerisourceBergen Drug Corp for the supply of Tolvaptan 30 mg tablets in unit dose packaging (10-count units). This firm fixed price contract, awarded on September 16, 2025, with an ultimate completion date of September 17, 2025, represents a non-set-aside competitive award. The pharmaceutical product will be delivered to the contractor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a delivery order valued at $21,076.03 to AmerisourceBergen Drug Corp for the supply of Tolvaptan 30 mg tablets in unit-dose packaging of 10 units. This firm fixed-price delivery order, awarded on December 15, 2025, with an ultimate completion date of December 16, 2025, represents a competitive procurement with no set-aside designation. The pharmaceutical product will be supplied from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 30, 2025, for the supply of Tolvaptan 15 mg tablets in unit-dose packaging (10 count). This is a firm fixed-price delivery order with a ceiling value of $12,218.27 and an ultimate completion date of October 31, 2025. The contract represents a non-set-aside, competitively awarded procurement and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $6,690.07 to AmerisourceBergen Drug Corp for Tolvaptan 15 mg tablets in unit dose packaging. This non-competitive delivery order, issued on August 5, 2025, with an ultimate completion date of August 6, 2025, represents a firm fixed price transaction for pharmaceutical supply. The contractor will perform this work at its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen...
- The Defense Logistics Agency awarded a $70,470.28 delivery order to AmerisourceBergen Drug Corp on December 15, 2025, for the supply of Tolvaptan 15 mg tablets in unit dose packages of 10. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award selection. Performance will be executed from the contractor's Conshohocken, Pennsylvania location, with an ultimate completion date of December 16, 2025. This delivery order is a child contract under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 17, 2025, for the supply of Tolvaptan 15 mg tablets in unit dose packages of 10 units. This is a firm fixed-price delivery order with a ceiling value of $5,100.87 and an ultimate completion date of July 18, 2025. The contract was awarded on a competitive basis without any set-aside designation. Performance will be executed from AmerisourceBergen's location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Tolvaptan 30 mg tablets in unit dose packaging of 10s. This contract is a non-set-aside, competitively awarded delivery order with firm fixed pricing, valued at $48,454.20, with a completion date of September 29, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FCXTRDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $33,218.27 to AmerisourceBergen Drug Corp for the supply of Tolvaptan 30 mg tablets in unit dose packages of 10. This is a firm fixed price, competitively awarded contract with no set-aside designation, issued on June 16, 2025, with an ultimate completion date of June 17, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location in Conshohocken, PA 19428. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of medications and medical products to support military healthcare programs worldwide. Tolvaptan, a vasopressin antagonist used in treating hyponatremia and polycystic kidney disease, represents one of the specialized pharmaceutical products delivered through this strategic contract vehicle to support Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $33.2k | 6/16/25 |